Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) EBITDA Margin (2021 - 2025)

Inmune Bio's EBITDA Margin history spans 5 years, with the latest figure at 19548.0% for Q1 2025.

  • For Q1 2025, EBITDA Margin rose 5827343.0% year-over-year to 19548.0%; the TTM value through Sep 2025 reached 99230.0%, down 24667.0%, while the annual FY2024 figure was 298985.71%, 27956120.0% down from the prior year.
  • EBITDA Margin for Q1 2025 was 19548.0% at Inmune Bio, up from 77821.43% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 4201.23% in Q1 2022 and bottomed at 113875.0% in Q1 2021.
  • The 5-year median for EBITDA Margin is 19548.0% (2025), against an average of 33253.56%.
  • The largest annual shift saw EBITDA Margin skyrocketed 10967377bps in 2022 before it tumbled -6059774bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 5860.12% in 2021, then rose by 5bps to 5556.7% in 2022, then crashed by -445bps to 30257.14% in 2023, then plummeted by -157bps to 77821.43% in 2024, then soared by 75bps to 19548.0% in 2025.
  • Per Business Quant, the three most recent readings for INMB's EBITDA Margin are 19548.0% (Q1 2025), 77821.43% (Q1 2024), and 30257.14% (Q4 2023).